Skip to main content

Table 2 Comparisons of demographic information and outcomes in the groups of high versus low concentration delivery

From: In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients

 

High concentration delivery

Low concentration delivery

p

No. of patients

84

80

 

Age (years)

56.0 (44.3, 65.8)

55 (44.5, 68.8)

0.920

Male, %

35 (42%)

36 (45%)

0.753

Ethnicity, %

0.268

 Caucasian

29 (35%)

36 (45%)

 

 African American

37 (44%)

31 (39%)

 

 Hispanic

15 (18%)

10 (13%)

 

 Asian

0

2 (3%)

 

 Other

3 (4%)

2 (1%)

 

Indication to use iEPO, %

 Hypoxemia

58 (69%)

56 (70%)

1.0

 Pulmonary hypertension

30 (36%)

25 (31%)

0.620

 Right heart failure

20 (24%)

14 (18%)

0.342

No. of patients had positive response to iEPO, %

 No. of patients had mPAP reduction ≥ 10%

46% (10/22)

47% (7/15)

1.0

 No. of patients had SpO2/FIO2 increment ≥ 10%

43% (25/58)

38% (21/56)

0.572

 No. of patients had SpO2/FIO2 increment ≥ 20%

26% (15/58)

18% (10/56)

0.368

 No. of patients had PaO2/FIO2 increment ≥ 10%

76% (34/45)

80% (28/35)

0.789

 No. of patients had PaO2/FIO2 increment ≥ 20%

69% (31/45)

63% (22/35)

0.637

iEPO duration, hours

42.0 (17.9, 94.6)

48.1 (18.1, 85.8)

0.868

iEPO weaning for survived patients

53

45

 

 Followed all steps to wean, %

96% (51/53)

71% (32/45)

< 0.001

 Extubated to iEPO via HFNC, %

17% (9/53)

2% (1/45)

0.038

Total number of syringes administered per patient

5 (3, 10)

12 (6, 22)

0.001

Duration of invasive ventilation, days

6 (3, 12)

9 (5, 18)

0.028

ICU length of stay, days

16 (8.3, 28)

15 (7.0, 30)

0.840

ECMO, %

10 (12%)

10 (13%)

1.0

Mortality, %

31 (37%)

35 (44%)

0.427

  1. iEPO inhaled epoprostenol, mPAP mean pulmonary arterial pressure, SpO2 saturation of pulse oximetry, FIO2 fraction of inspired oxygen, PaO2 partial pressure of arterial oxygen, ICU intensive care unit, ECMO extracorporeal membrane oxygenation